Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Intensity-Modulated Radiotherapy for Lung Cancer Current Status and Future Developments

Intensity-Modulated Radiotherapy for Lung Cancer Current Status and Future Developments Steat of the a tr : Con Ci Se r eview Intensity-Modulated Radiotherapy for Lung Cancer:  Current Status and Future Developments Clara Chan, MD,* Stephanie Lang, MSc,‡ Carl Rowbottom, PhD,*† Matthias Guckenberger, MD,‡ and Corinne Faivre-Finn, MD, PhD,* On behalf of the IASLC Advanced Radiation Technology Committee progression-free survival and overall survival (OS) rates in Abstract: Radiotherapy plays an important role in the management locally advanced NSCLC remain low (30% and 10–15% at 5 of lung cancer, with over 50% of patients receiving this modality at 1,2,4 years, respectively). some point during their treatment. Intensity-modulated radiotherapy Currently, the standard dose/fractionation for patients (IMRT) is a technique that adds fluence modulation to beam shap- with stage III NSCLC is 60 Gy equivalent dose in 2 Gy/frac- ing, which improves radiotherapy dose conformity around the tumor tion (EQD2). One potential reason for low progression-free and spares surrounding normal structures. Treatment with IMRT is survival and OS rates in this group may be that this radiother- becoming more widely available for the treatment of lung cancer, apy dose is perhaps too low to achieve local control. Martel despite the paucity of high level evidence supporting the routine use et al. estimated that doses of 84 Gy in EQD2 are required http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Intensity-Modulated Radiotherapy for Lung Cancer Current Status and Future Developments

Faivre-Finn, Corinne
Journal of Thoracic Oncology , Volume 9 (11) – Nov 1, 2014
Download PDF
11 pages

Loading next page...
 
/lp/wolters-kluwer-health/intensity-modulated-radiotherapy-for-lung-cancer-current-status-and-C0reQiLsF5

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000346
pmid
25436795
Publisher site
See Article on Publisher Site

Abstract

Steat of the a tr : Con Ci Se r eview Intensity-Modulated Radiotherapy for Lung Cancer:  Current Status and Future Developments Clara Chan, MD,* Stephanie Lang, MSc,‡ Carl Rowbottom, PhD,*† Matthias Guckenberger, MD,‡ and Corinne Faivre-Finn, MD, PhD,* On behalf of the IASLC Advanced Radiation Technology Committee progression-free survival and overall survival (OS) rates in Abstract: Radiotherapy plays an important role in the management locally advanced NSCLC remain low (30% and 10–15% at 5 of lung cancer, with over 50% of patients receiving this modality at 1,2,4 years, respectively). some point during their treatment. Intensity-modulated radiotherapy Currently, the standard dose/fractionation for patients (IMRT) is a technique that adds fluence modulation to beam shap- with stage III NSCLC is 60 Gy equivalent dose in 2 Gy/frac- ing, which improves radiotherapy dose conformity around the tumor tion (EQD2). One potential reason for low progression-free and spares surrounding normal structures. Treatment with IMRT is survival and OS rates in this group may be that this radiother- becoming more widely available for the treatment of lung cancer, apy dose is perhaps too low to achieve local control. Martel despite the paucity of high level evidence supporting the routine use et al. estimated that doses of 84 Gy in EQD2 are required

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Nov 1, 2014

References

  • Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer
    Aupérin
  • Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma
    Machtay
  • European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer
    De Ruysscher
  • Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients
    Le Chevalier
  • Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients
    Martel
  • Stereotactic radiation therapy: changing treatment paradigms for stage I nonsmall cell lung cancer
    Palma
  • A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617
    Bradley
  • High-dose radiotherapy in inoperable nonsmall cell lung cancer: comparison of volumetric modulated arc therapy, dynamic IMRT and 3D conformal radiotherapy
    Bree
  • Treatment planning comparison between conformal radiotherapy and helical tomotherapy in the case of locally advanced-stage NSCLC
    Cattaneo
  • The superiority of hybrid-volumetric arc therapy (VMAT) technique over double arcs VMAT and 3D-conformal technique in the treatment of locally advanced non-small cell lung cancer–a planning study
    Chan
  • Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer
    Liu
  • Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer
    Murshed
  • Stereotactic radiotherapy for peripheral lung tumors: a comparison of volumetric modulated arc therapy with 3 other delivery techniques
    Ong
  • Comparison of anisotropic aperture based intensity modulated radiotherapy with 3D-conformal radiotherapy for the treatment of large lung tumors
    Simeonova
  • Members of the IMRT Indications Expert Panel. . Intensity-modulated radiotherapy in the treatment of lung cancer
    Bezjak
  • A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma
    Lee
  • Preliminary results of a phase I/II study of simultaneous modulated accelerated radiotherapy for nondisseminated nasopharyngeal carcinoma
    Lee
  • Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial
    Nutting
  • Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer
    Sharma
  • Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma
    Allen
  • Intensity-modulated radiation therapy, protons, and the risk of second cancers
    Hall
  • Does incidental irradiation with doses below 50 gy effectively reduce isolated nodal failures in non-small-cell lung cancer: dose–response relationship
    Kepka
  • Intensity-modulated radiotherapy: current status and issues of interest
    Intensity Modulated Radiation Therapy Collaborative Working Group